Drugs / pixantrone dimaleate
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Pixuvri | — | 2024-06-12 | europa.eu ↗ |
| Approved | EU (EMA) | Pixuvri | — | 2012-05-10 | europa.eu ↗ |
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00551239 | Aug 2007 → ? | leukemia, lymphoma | CTI BioPharma | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pixantrone dimaleate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00551239 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as fludarabine and pixantrone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.” NCT00551239 ↗ |